Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS). MS is characterised by damage to myelin, but there are no approved therapies… Read More
mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say. Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More
Biotechnology company Pheno Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead therapeutic candidate PTD802 targeting multiple sclerosis (MS). The clearance follows a clinical trial authorisation (CTA) from the UK’s MHRA at the start… Read More
Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer. Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Lundgren recently served… Read More
Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties. For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral… Read More
Researchers from University of California San Diego School of Medicine have discovered that children living with multiple sclerosis (MS) show signs of accelerated biological ageing, even in their teenage years. The research published in Neurology, the medical journal of the American Academy of Neurology, is… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More
News round-up for 21-25 April by DDW Senior Digital Content Editor Diana Spencer. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. Read More
The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns… Read More
Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. The clinical trial results and case studies were presented in posters and a company-sponsored symposium at the 40th Congress of the European Committee for Treatment and Research in Multiple… Read More
Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in… Read More
An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and… Read More
FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,”… Read More
GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of Covid-19, (PASC, post-Covid or long Covid), has entered into a credit agreement for a total amount of up to €25 million with the… Read More
Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this new on-demand webinar we use multiple sclerosis as a case-study… Read More
Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at… Read More
